Perkin Elmer has launched the Lance Ultra cAMP Detection Kit designed for the screening and profiling of G-protein coupled receptors (GPCRs) as tools in the search for potential therapeutics.
The Lance kit facilitates pharmacological studies of challenging receptors involved in several diseases, including cancer and inflammatory, metabolic and neurodegenerative disorders.
The increased sensitivity of the Lance Ultra cAMP Detection Kit enables scientists to detect low levels of cAMP without the need to re-engineer cell lines, saving time and resources.
The assay uses a proven TR-Fret protocol for easy and precise adoption in a range of HTS applications, including 1,536-well formats.
Furthermore, as many high-throughput assays fail to generate reproducible data when cAMP levels are very low, the kit is said to maximise signal stability and provides new insights into GPCRs.
Lance Ultra utilises Perkin Elmer's Ulight emission dye, for high efficiency and good signal-to-noise ratios.
Lance Ultra is optimised for use in high-throughput and ultra-high throughput screening applications for detection and analysis of protein activity for research purposes.
